Consensus PHAXIAM Therapeutics S.A.

Equities

PHXM

FR001400K4B1

End-of-day quote Euronext Paris Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
3.055 ^EUR	+0.99%		+3.91%	-33.59%

Apr. 15	Phaxiam initiates trial in infective endocarditis	CF
Apr. 15	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

Evolution of the average Target Price on PHAXIAM Therapeutics S.A.

Price target over the last 5 years

History of analyst recommendation changes

87ca6e8cc5e3d4c532a38635c68ab2.vWJCpYRNOI9REPdcgg1lCmFsYkVh6WHmctfcrTlWMew.xQ8rwew6bfskXJI-9HQyZSUkBRAyigKlMbaV-EMOeb_wMADhwAUIvjh5sg~0b1f096cf328144b2b2348ac7fe4143b

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.055 EUR

Average target price

6.85 EUR

Spread / Average Target

+124.22%

High Price Target

8 EUR

Spread / Highest target

+161.87%

Low Price Target

5.7 EUR

Spread / Lowest Target

+86.58%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar